Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/EUCTR2020-003371-18-IT
EUCTR2020-003371-18-ITActive, not recruitingPhase 1

Phase 1/2 Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of Marzeptacog alfa (activated) in Treatment of Episodic Bleeding in Subjects with Inherited Bleeding Disorders - MAA-202

Catalyst Biosciences, Inc.0 sites24 target enrollmentStarted: May 24, 2021Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Enrollment
24
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • •1) Confirmed diagnosis of cohort:
  • •a) Confirmed diagnosis of congential FVIID
  • •b) Confirmed diagnosis of congenital GT (ie, platelet function analyzer, mutational analysis)
  • •c) Confirmed diagnosis of congenital HAwI-E treated with the same dose of emicizumab for at least 4 weeks and with one of the following:
  • •i) Titer =5 BU
  • •ii) Titer =0.6 BU but expected to have a high anamnestic response to FVIII, as demonstrated from the subject’s medical history, precluding the use of FVIII products to treat bleeding as documented by the Investigator
  • •iii) Titer =0.6 BU but expected to be refractory to increased dosing of FVIII, as demonstrated from the subject’s medical history, precluding the use of FVIII products to treat bleeding as documented by in the Investigator
  • •Note: documentation of highest historic titer should be recorded.
  • •2) History of bleeding with an
  • •a) ABR of =8 for FVIID
  • •b) ABR of =8 for GT
  • •c) ABR of =1 for HAwI-E
  • •3) Male or female, age =12 years
  • •4) Agreement to use highly effective birth control throughout the study if the subject has childbearing potential
  • •5) If female, the subject must meet the following criteria:
  • •a) Not currently be breastfeeding
  • •b) Not plan on becoming pregnant during the study
  • •c) Be surgically sterile, or at least 2 years postmenopausal, or have a negative serum pregnancy test at Screening (Visit 1)
  • •6) Affirmation of informed consent with signature confirmation and assent for children from age 12 to 17 years before any study-related activities
  • •Note: study-related activities are any procedure that would not have been performed during normal clinical management of the subject
  • •7) Stated willingness to comply with all study procedures and availability for the duration of the study
  • •8) Investigator confirmed subject’s ability to rapidly assess a bleeding episode and respond appropriately
  • •9) Investigator confirmed subject’s ability to administer MarzAA SC at home
  • •Are the trial subjects under 18? yes
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range 10
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range 6

Exclusion Criteria

  • •1) Cohort 1: genotype of FVIID subjects with following mutations:
  • •a) P.A354V-p.464Hfs
  • •b) P.Ser112-Stop (homozygous)
  • •c) Ala294Val + Del C
  • •d) 100GLN - ARG shift
  • •e) Ser103 - Gly
  • •Note: documentation of historic genotype would be acceptable
  • •2) Inability to discontinue and washout any prophylactic (except Hemlibra) or episodic treatment for 5 days and 10 days for platelet transfusion prior to dosing
  • •3) Previous participation in a clinical study involving SC administration of wt-rFVIIa (NovoSeven or MOD-5014) or any study using a modified amino-acid sequence FVIIa (other than MarzAA) such as: NN1731 or BAY86-6150.
  • •Note: Prior participation in a study of intravenous (IV) LR769, rFVIIa-FP (CSL689), or MarzAA is permissible
  • •4) Previous participation in a clinical study with treatment within the previous 30 days or =5 half-lives (of the investigation product) or absence of clinical effect, whichever is longer
  • •5) Known positive antibody to FVIIa or variants thereof detected during screening or prior to Day 1
  • •6) Known hypersensitivity to pd-FVIIa, pd-FVII, wt-rFVIIa, or MarzAA or any of the excipients or related products
  • •7) Treatment with anticoagulants or antiplatelet therapy within 1 week of enrollment or anticipated need during the study
  • •8) Planned elective surgery within 12 months following study entry
  • •9) History of clinically relevant coagulation blood disorders
  • •10) CD 4 T cell count of <200 cells/mm3
  • •11) Platelet count <50,000 /µL based on screening laboratory assessments
  • •12) Current or history of advanced atherosclerotic disease (ie, known history of coronary artery disease, ischemic stroke, etc), or deep venous thrombosis (DVT) within 24 months of dosing or considered to be at a high risk of venous thromboembolic event (VTE) as judged by the Investigator
  • •13) Compromised hepatic or renal function:
  • •a) Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels =5 × the upper limit of normal (ULN)
  • •b) Total bilirubin level =2 mg/dL (>35 µmol/L) unless there is a known history of Gilbert’s syndrome
  • •c) Serum creatinine level >1.25 × ULN
  • •14) Inability or medical, psychosocial, or familial issues that might prevent full participation and cooperation with the procedures and requirements of the clinical study as determined by the potential subject and physician/Investigator
  • •15) Weight =105 kg

Investigators

Similar Trials

Unknown
Phase 1
Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders
CTRI/2021/03/032089Catalyst Biosciences Inc8
Completed
Phase 2
A Phase II Study of MR19A13A.
JPRN-jRCT2051220112obuyo Oya12
Completed
Phase 2
Phase II study to evaluate pharmacodynamics, pharmacokinetics and safety after cyclic dose or continuous dose of FSN-013 for 3 cycles in Japanese healthy adult female subjectsdysmenorrhea
JPRN-jRCT2080223983Fuji Pharma Co., Ltd.60
Active, not recruiting
Phase 1
Study of how tafluprost is distributed in blood circulation after ocular administration in children who have glaucoma or elevated intraocular pressure. Tolerance to the drug and safety in general will also be assessed.Glaucoma or Ocular HypertensionMedDRA version: 18.1 Level: PT Classification code 10011762 Term: Cystic fibrosis System Organ Class: 10010331 - Congenital, familial and genetic disorders
EUCTR2013-004302-26-GBSanten Oy18
Active, not recruiting
Phase 1
Study of how tafluprost is distributed in blood circulation after ocular administration in children who have glaucoma or elevated intraocular pressure. Tolerance to the drug and safety in general will also be assessed.Glaucoma or Ocular HypertensionMedDRA version: 18.1Level: PTClassification code 10011762Term: Cystic fibrosisSystem Organ Class: 10010331 - Congenital, familial and genetic disorders
EUCTR2013-004302-26-SKSanten Oy18
Study to Evaluate the Pharmacokinetics,... | Clinical Trial